Newsroom | 4906 results
Sorted by: Latest
-
Open Letter to SNMMI Board of Directors and President Dr. Prabhu Ethiraj: TeamBest Global Calls for Strengthened Collaboration to Advance Theranostics and Expand Cancer Diagnosis and Treatment Options
WASHINGTON--(BUSINESS WIRE)--Dr. Krishnan Suthanthiran, President/Founder of TeamBest Global (TBG) companies and the International Society for Radiation Medicine & Molecular Imaging (ISRMMI), is urging closer collaboration with the Society of Nuclear Medicine and Molecular Imaging (SNMMI) to accelerate the adoption of theranostics and broaden treatment options for cancer patients worldwide. TBG has long been recognized for developing cost-effective, innovative technologies, and advanced the...
-
Orano Med Enters Next Phase of Collaboration With Roche
CHÂTILLON, France--(BUSINESS WIRE)--Orano Med's collaboration with Roche to develop “two-step pretargeted radioimmunotherapy” (or PRIT) ready to advance into clinical development....
-
RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI gadolinium-based contrast agent (GBCA) gadoquatrane. QUANTI Pediatric evaluated gadoquatrane in children with known or suspected disease undergoing contrast-enhanced magnetic resonance imaging (MRI) at a gadolinium dose of 0.04 mmol Gd/kg body weight, representing a dose reduction...
-
GE HealthCare and Mayo Clinic unveil GEMINI-RT: A bold research collaboration in radiation therapy and advanced cancer care
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) and Mayo Clinic today announced the GE HealthCare-Mayo Clinic Initiative in Radiation Therapy, known as GEMINI-RT, an ambitious new collaboration that aims to transform personalized radiation therapy and cancer care. Building on decades of collaboration and the original Strategic Radiology Research Collaboration signed in 2023, GEMINI-RT plans to drive innovation in prediction, planning, automation, workflow and monitoring for radiation onc...
-
University of Rochester Medical Center and GE HealthCare form seven-year Care Alliance to build advanced capabilities across system
ROCHESTER, N.Y.--(BUSINESS WIRE)--University of Rochester Medical Center (URMC) and GE HealthCare (Nasdaq: GEHC) announce a Care Alliance to build advanced capabilities across URMC’s footprint in upstate New York, including a center of excellence in its Imaging Sciences department, the addition of diagnostic tracer production for molecular imaging applications, and the standardization of patient monitoring across the entire UR Medicine health system. The newly formed Care Alliance spans seven y...
-
bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable
SAN ANTONIO, Texas--(BUSINESS WIRE)--bioAffinity Technologies will present case studies at NLCRT in which CyPath® Lung identified Stage 1A lung cancer in high-risk patients....
-
AdvanCell beginnt mit Phase-2-Erweiterungsstudie zu ADVC001, einer neuartigen gezielten Alpha-Therapie für Prostatakrebs
SYDNEY & BOSTON--(BUSINESS WIRE)--AdvanCell, ein Radiopharmazieunternehmen im klinischen Stadium, das innovative zielgerichtete Alpha-Therapien für Krebs entwickelt, gab heute den Start der TheraPb-Phase-2-Erweiterungsstudie (NCT05720130) bekannt, in der sein führender Prüfkandidat ADVC001 bei metastasiertem Prostatakrebs untersucht wird. Die Nachricht folgt auf die vielversprechenden Ergebnisse der Phase-1b-Dosiseskalationsstudie, die auf dem Kongress der European Society for Medical Oncology...
-
AdvanCell lance un essai d'expansion de phase 2 pour l'ADVC001, une nouvelle thérapie alpha ciblée contre le cancer de la prostate
SYDNEY et BOSTON--(BUSINESS WIRE)--AdvanCell, une société radiopharmaceutique de phase clinique développant des thérapies alpha ciblées innovantes contre le cancer, annonce aujourd’hui le lancement de l’essai d’expansion de phase 2 TheraPb (NCT05720130) évaluant son candidat phare expérimental, ADVC001, dans le cancer métastatique de la prostate. Cette annonce fait suite aux résultats encourageants de l’augmentation de la dose de phase 1b présentés au congrès 2025 de la Société européenne d’onc...
-
Samenvatting: AdvanCell start een Fase 2-uitbreidingsstudie van ADVC001, een nieuwe doelgerichte alfatherapie ter behandeling van prostaatkanker
SYDNEY & BOSTON--(BUSINESS WIRE)--AdvanCell, een radiofarmaceutisch bedrijf in klinische fase dat innovatieve doelgerichte alfatherapieën ter behandeling van kanker ontwikkelt, kondigde vandaag de aanvang aan van de TheraPb Fase 2-uitbreidingsstudie (NCT05720130) om haar belangrijkste onderzoekskandidaat-geneesmiddel, ADVC001, voor metastatische prostaatkanker te evalueren. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten w...
-
Resumen: AdvanCell inicia el ensayo ampliado de fase 2 de ADVC001, una nueva terapia alfa dirigida para cáncer de próstata
SÍDNEY y BOSTON--(BUSINESS WIRE)--AdvanCell, una empresa radiofarmacéutica de fase clínica que desarrolla terapias alfa dirigidas innovadoras para el cáncer, anunció hoy el inicio del ensayo ampliado de fase 2 TheraPb (NCT05720130) para evaluar a su principal candidato en investigación, ADVC001, para cáncer de próstata metastásico. El comunicado en el idioma original es la versión oficial y autorizada del mismo. Esta traducción es solamente un medio de ayuda y deberá ser comparada con el texto...
